Roche Signs Deals with Ipsen and Aspreva
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 42 (Table of Contents)
Published: 3 Dec-2003
DOI: 10.3833/pdr.v2003.i42.846 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Roche acquired rights to glucagon-like-peptide-1 (GLP-1) receptor agonist BIM51077 for treating Type II diabetes and other GLP-1 analogues from Ipsen...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS